Loading...
•
Jun 30, 2021
Eagle Q2 2021 Earnings Report
Reported second quarter 2021 results with increased revenue and progress in product development.
Key Takeaways
Eagle Pharmaceuticals reported a strong Q2 2021 with total revenue of $48.1 million, driven by higher product sales of BELRAPZO® and RYANODEX®. The company also announced a licensing agreement for Landiolol and anticipates the commercial launch of vasopressin by year-end.
Total revenue for Q2 2021 was $48.1 million, compared to $41.9 million in Q2 2020.
Net income for Q2 2021 was $3.6 million, or $0.28 per basic share and $0.27 per diluted share.
Adjusted non-GAAP net income for Q2 2021 was $12.4 million, or $0.95 per basic share and $0.93 per diluted share.
The company announced a licensing agreement for U.S. commercial rights to Landiolol.
Eagle
Eagle
Forward Guidance
Eagle Pharmaceuticals expects approximately $20-$25 million from combined royalty and milestone revenue next year for TREAKISYM (bendamustine), if TREAKISYM RI formulation is approved
Positive Outlook
- Potential for $20-$25 million in royalty and milestone revenue from TREAKISYM.
- PEMFEXY™ launch in February 2022, allowing an initial period of exclusivity.
- Landiolol solidifies hospital and critical care product portfolio.
- Leveraging current sales force for Landiolol with little additional infrastructure costs.
- Pursuing other opportunities to build value for the company.